Gunderson Capital Management’s BRAINSTORM CELL THERAPUTC BCLI Stock Holding History

Gunderson Capital Management’s Portfolio BCLI Stock Details BCLI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-25,950	Closed	-$29.1K	–	55
2025 Q2	$29.1K	Buy	+25,950	New	+$29K	0.01%	46

Other funds holding BCLI

Osaic Holdings Scottsdale, Arizona $85.1B AUM 27.35% 1-Year Est. Return

BSB

Bangor Savings Bank Bangor, Maine $1.36B AUM 19.29% 1-Year Est. Return

VWA

VSM Wealth Advisory Hunt Valley, Maryland $376M AUM 21.56% 1-Year Est. Return

SPIA

Steward Partners Investment Advisory New York $19.6B AUM 29.84% 1-Year Est. Return

DJSG

D.J. St. Germain Springfield, Massachusetts $2.78B AUM 23.87% 1-Year Est. Return

Gunderson Capital Management's BCLI Position: Q3 2025 in Review

Gunderson Capital Management sold out of BRAINSTORM CELL THERAPUTC (BCLI) in Q3 2025, closing a stake of 25,950 shares — an estimated $29.1K sold.

Gunderson Capital Management first reported a position in BCLI in Q2 2025 and held it in 1 quarter. The position peaked at $29.1K in Q2 2025. 5 funds tracked by Wall St. Rank hold BCLI as of Q3 2025.

Gunderson Capital Management reported no remaining BRAINSTORM CELL THERAPUTC position as of Q3 2025 after selling out during the quarter.
Gunderson Capital Management sold 25,950 BRAINSTORM CELL THERAPUTC shares in Q3 2025, an estimated $29.1K.
Gunderson Capital Management first reported a position in BRAINSTORM CELL THERAPUTC in Q2 2025 and held it in 1 quarter.
Gunderson Capital Management's BRAINSTORM CELL THERAPUTC position peaked at $29.1K in Q2 2025.
5 funds tracked by Wall St. Rank held BRAINSTORM CELL THERAPUTC as of Q3 2025.

Based on Gunderson Capital Management's 13F filing for Q3 2025, filed 22 Oct 2025.